ArticleHeart rhythm O22025
Pacing-induced cardiomyopathy following leadless and transvenous pacemaker implantation: A multicenter retrospective study.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The "Double Hit" in leadless pacing: Acute heart failure from mechanical sensing failure and ventricular dyssynchrony rescued by cardiac resynchronization therapy.HeartRhythm case reports · 2026Article
- Advanced Cardiac Imaging for Risk Prediction of Pacing-Induced Cardiomyopathy: A Narrative Literature Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pacing-induced cardiomyopathy (PICM) has been reported among patients with transvenous pacemakers (TVP). Recent reports have suggested that the incidence may be lower among patients with leadless pacemakers (LP). We performed a multicenter retrospective study to better define these rates and to identify any potential risk factors. Objective: To determine the rates of PICM between LP and TVP and risk factors for development of PICM in each cohort. Methods: Patients implanted with either a Micra transcatheter LP or TVP between November 2015 and January 2022 were identified from medical records at 3 large medical centers. PICM was defined as a decrease in left ventricular ejection fraction (LVEF) from pre-implant in patients with a baseline LVEF of ≥50% with a resulting post-implant LVEF ≤40% who received at least 20% ventricular pacing. Logistic regression was used to determine univariate and multivariable predictors of PICM. Results: A total of 176 patients with LP and 522 patients with TVP implantations were included for analysis. Of these, 6.3% of patients with LP and 7.9% of patients with TVP developed PICM (odds ratio [OR]: 0.78, 95% confidence interval [CI]: 0.39-1.56, Conclusion: PICM rates are comparable between LP and TVP implantation. Prolonged paced QRS is a predictor for development of PICM and higher pre-implantation LVEF is protective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.